Piramal Pharma, headquartered in Mumbai, India, has completed the acquisition of an additional nearly 40.7% stake in Yapan Bio Private Ltd., a Hyderabad-based contract development and manufacturing organization (CDMO) specializing in vaccines and biologics.

The INR 76 crore ($7.95 million) transaction, finalized Aug. 18, increases Piramal’s ownership of Yapan Bio to 74%, making the company a subsidiary. Yapan Bio will continue operating within Piramal Pharma Solutions (PPS), the company’s CDMO business.

The acquisition is intended to expand Piramal’s large-molecule development and manufacturing capabilities and integrate Yapan Bio’s services into the company’s broader CDMO network. The expanded capabilities will support development and scale-up of complex biologic therapies.

Yapan Bio also supports PPS’ antibody-drug conjugate (ADC) development services, providing capabilities that complement the company’s integrated development offering for early-stage ADC programs.

The acquisition follows a recent expansion of PPS’ peptide manufacturing capabilities in India. Earlier this month, the company announced a new spray drying suite at its Turbhe facility designed for small-volume, high-potency batches of peptide active pharmaceutical ingredients (APIs), highly potent APIs, and other complex biomolecules. The closed-loop suite includes Band 5 containment and can process feed rates of up to 1 liter per hour.